IBI Ag Announces Successful Development of AI-Driven De Novo Protein Design Platform for Bioinsecticides

Rhea-AI Summary

IBI Ag (OTC:TRNGF) announced on March 10, 2026 completion of a proof of concept for an AI-driven de novo protein design platform for bioinsecticides. The POC produced novel proteins validated in insect bioassays, showing efficacy against key agricultural pests and enabling greenhouse and field trial plans.

The platform leverages proprietary biological data and IP to target pests selectively, aiming to reduce impact on beneficial insects while improving stability, shelf life, and production economics.

Positive

• POC produced de novo proteins validated in insect bioassays
• AI-driven platform leverages proprietary biological data and IP
• Company plans greenhouse and field trials in upcoming growing seasons

Negative

• Results limited to POC and insect bioassays; no greenhouse/field data yet
• Commercialization timing and regulatory pathway remain unspecified

Market Reality Check

Price: $0.0300 Vol: Volume 320,000 is 19.82x ...

high vol

$0.0300 Last Close

Volume Volume 320,000 is 19.82x the 20-day average of 16,147, indicating unusually heavy trading before this AI platform news. high

Technical Price at 0.03 is below the 200-day MA of 0.05 and sits at the 52-week low, 50.5% under the 52-week high of 0.0606.

Peers on Argus

TRNGF fell 43.18% while key peers in Financial Services/Asset Management showed ...

TRNGF fell 43.18% while key peers in Financial Services/Asset Management showed mixed, modest moves: BXLC at -1.16%, TETAA at +0.32%, OFSTF at +0.33%, with others flat. This points to a stock-specific move rather than a sector-wide shift.

Market Pulse Summary

This announcement details completion of a proof of concept for an AI-driven de novo protein design p...

Analysis

This announcement details completion of a proof of concept for an AI-driven de novo protein design platform creating novel bioinsecticide proteins, validated in insect bioassays against key pests. The company plans greenhouse and field trials in coming growing seasons, aiming for environmentally focused pest control with potential cost and stability benefits. With no prior tagged history provided, investors may track subsequent trial data, regulatory paths, and partnership activity as key validation points for this technology.

AI-generated analysis. Not financial advice.

POC included in vivo insect validation of de novo designed proteins

NES TZIONA, Israel, March 10, 2026 /PRNewswire/ -- IBI Ag Ltd. ('IBI Ag'), a leader in sustainable agricultural solutions, has today announced the successful completion of its proof of concept (POC) for the AI-driven platform for de novo design of novel bioinsecticide proteins. This groundbreaking advancement marks a significant step forward in the quest for innovative, environmentally friendly pest control solutions.

The POC included the design of new proteins, successfully validated in insect bioassays, demonstrating their efficacy against key agricultural pests. By leveraging cutting-edge AI technology and proprietary biological data and IP, IBI Ag has developed a novel approach to computationally design bioinsecticide proteins that selectively and effectively target pests while aiming to minimize the impact on beneficial insects and the environment.

This innovative methodology represents a paradigm shift in the development of bioinsecticides, offering a faster and more efficient path to market. The de novo design opens up many new markets by targeting insect challenges that were previously unattainable with naturally occurring proteins, while also optimizing commercial aspects such as lower production costs, longer shelf life, stability, and resiliency.

"Completing this proof of concept is a major milestone for IBI Ag," said Arnon Heyman, CEO of IBI Ag. "To the best of our knowledge, this is the first ever de novo protein design platform for bioinsecticides. It is designed to leverage the company's proprietary IP for targets in insect control. This allows us to discover and validate new proteins based on vast amounts of data which we believe is a game-changer in the industry. This advancement not only demonstrates our commitment to sustainability but also supports farmers in achieving higher yields without compromising the health of ecosystems."

The successful discovery and validation of these new bioinsecticide proteins pave the way for significant expansion of IBI Ag's development pipeline, with plans for greenhouse and field trials in the coming growing seasons. IBI Ag is dedicated to collaborating with agricultural partners and stakeholders to bring these innovative solutions to farmers worldwide.

For more information about IBI Ag and its cutting-edge research, please visit https://www.ibi-ag.com/.

About IBI Ag: IBI Ag is a pioneer in the agri-biotech industry, developing innovative and sustainable crop protection solutions. The company's proprietary nanobody technology provides a new mode of action for controlling a broad range of insect pests with minimal ecological footprint. Founded by The Trendlines Group (SGX: 42T) (OTCQX: TRNLY), together with Prof. Amir Ayali and Dr. Rony Oren Benaroya, and supported by the Israel Innovation Authority, IBI Ag is redefining the future of pest management.

Media Contact: Arnon Heyman, CEO – IBI Ag Email: Arnon.heyman@ibi-ag.com

Logo - https://mma.prnewswire.com/media/2818692/IBIAG_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/ibi-ag-announces-successful-development-of-ai-driven-de-novo-protein-design-platform-for-bioinsecticides-302709316.html

SOURCE IBI Ag

FAQ

What did IBI Ag (TRNGF) announce on March 10, 2026 about its AI platform?

They completed a proof of concept for an AI-driven de novo protein design platform validated in insect bioassays. According to the company, the POC yielded novel bioinsecticide proteins effective against key pests and enabled plans for greenhouse and field trials.

How were the new bioinsecticide proteins tested by IBI Ag (TRNGF)?

They were validated in in vivo insect bioassays demonstrating efficacy against target agricultural pests. According to the company, these assays showed selective activity and support moving into greenhouse and field testing in coming seasons.

What advantages does IBI Ag (TRNGF) claim for its de novo design approach?

The company says the approach enables targeting previously unattainable insect challenges and improves production attributes. According to the company, expected benefits include lower production costs, longer shelf life, stability, and reduced impact on beneficial insects.

Will IBI Ag (TRNGF) conduct field trials for the new proteins and when?

Yes, the company plans greenhouse and field trials in upcoming growing seasons to further validate performance. According to the company, these trials are the next step toward commercialization following successful POC bioassays.

Does the IBI Ag (TRNGF) announcement guarantee commercial availability of the bioinsecticides?

No, the announcement reports POC success but does not guarantee commercial availability or regulatory approvals. According to the company, additional greenhouse, field testing and subsequent steps remain before market entry.